+

WO2004096124A3 - Compositions et procedes pour le diagnostic et le traitement de tumeurs - Google Patents

Compositions et procedes pour le diagnostic et le traitement de tumeurs Download PDF

Info

Publication number
WO2004096124A3
WO2004096124A3 PCT/US2003/009992 US0309992W WO2004096124A3 WO 2004096124 A3 WO2004096124 A3 WO 2004096124A3 US 0309992 W US0309992 W US 0309992W WO 2004096124 A3 WO2004096124 A3 WO 2004096124A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
tumor
diagnosis
treatment
methods
Prior art date
Application number
PCT/US2003/009992
Other languages
English (en)
Other versions
WO2004096124A2 (fr
Inventor
Daryl T Baldwin
Hilary Clark
Sherry Heldens
Sothy Yi
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to EP03736450A priority Critical patent/EP1608967A4/fr
Priority to CA002519241A priority patent/CA2519241A1/fr
Priority to PCT/US2003/009992 priority patent/WO2004096124A2/fr
Priority to JP2004571401A priority patent/JP2007521791A/ja
Priority to AU2003237792A priority patent/AU2003237792A1/en
Publication of WO2004096124A2 publication Critical patent/WO2004096124A2/fr
Publication of WO2004096124A3 publication Critical patent/WO2004096124A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)

Abstract

L'invention concerne des compositions utiles pour le diagnostic et le traitement de tumeurs chez des mammifères, et des procédés relatifs à l'utilisation de ces compositions pour les mêmes besoins.
PCT/US2003/009992 2003-04-01 2003-04-01 Compositions et procedes pour le diagnostic et le traitement de tumeurs WO2004096124A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP03736450A EP1608967A4 (fr) 2003-04-01 2003-04-01 Compositions et procedes pour le diagnostic et le traitement de tumeurs
CA002519241A CA2519241A1 (fr) 2003-04-01 2003-04-01 Compositions et procedes pour le diagnostic et le traitement de tumeurs
PCT/US2003/009992 WO2004096124A2 (fr) 2003-04-01 2003-04-01 Compositions et procedes pour le diagnostic et le traitement de tumeurs
JP2004571401A JP2007521791A (ja) 2003-04-01 2003-04-01 腫瘍の診断と治療のための組成物と方法
AU2003237792A AU2003237792A1 (en) 2003-04-01 2003-04-01 Compositions and methods for the diagnosis and treatment of tumor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/009992 WO2004096124A2 (fr) 2003-04-01 2003-04-01 Compositions et procedes pour le diagnostic et le traitement de tumeurs

Publications (2)

Publication Number Publication Date
WO2004096124A2 WO2004096124A2 (fr) 2004-11-11
WO2004096124A3 true WO2004096124A3 (fr) 2004-12-29

Family

ID=33415184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/009992 WO2004096124A2 (fr) 2003-04-01 2003-04-01 Compositions et procedes pour le diagnostic et le traitement de tumeurs

Country Status (5)

Country Link
EP (1) EP1608967A4 (fr)
JP (1) JP2007521791A (fr)
AU (1) AU2003237792A1 (fr)
CA (1) CA2519241A1 (fr)
WO (1) WO2004096124A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6882782B2 (ja) 2015-08-04 2021-06-02 デューク ユニバーシティ 遺伝子コードされた本質的に無秩序な送達用ステルスポリマーおよびその使用方法
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
WO2017210476A1 (fr) 2016-06-01 2017-12-07 Duke University Biocapteurs ne s'encrassant pas
CN109890833A (zh) 2016-09-14 2019-06-14 杜克大学 用于递送亲水性药物的基于三嵌段多肽的纳米粒子
CN110023326A (zh) 2016-09-23 2019-07-16 杜克大学 具有lcst行为的非结构化无重复多肽
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2019006374A1 (fr) 2017-06-30 2019-01-03 Duke University Ordre et désordre en tant que principe de conception pour des réseaux de biopolymère sensibles à des stimuli
WO2019032973A1 (fr) 2017-08-10 2019-02-14 Washington University Compositions et méthodes de traitement utilisant un mononucléotide de nicotinamide
US12296018B2 (en) 2018-01-26 2025-05-13 Duke University Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same
WO2019183476A1 (fr) * 2018-03-23 2019-09-26 Duke University Conjugués biopolymère-immunotoxine à libération prolongée et leurs procédés d'utilisation
WO2019213150A1 (fr) 2018-04-30 2019-11-07 Duke University Plateforme d'administration de médicament à base de polymère de type peg sensible aux stimuli
WO2020028806A1 (fr) 2018-08-02 2020-02-06 Duke University Protéines de fusion à double agoniste
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080842A2 (fr) * 2001-04-05 2002-10-17 Estetecon Ab Medicament et procede de diagnostic d'un etat auto-immun

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
WO1991000360A1 (fr) 1989-06-29 1991-01-10 Medarex, Inc. Reactifs bispecifiques pour le traitement du sida
CA2071483C (fr) 1989-10-24 2001-04-17 Mark Matteucci Analogues d'oligonucleotides avec nouvelles liaisons
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
WO1992020373A1 (fr) 1991-05-14 1992-11-26 Repligen Corporation Anticorps d'heteroconjugues pour le traitement des infections a l'hiv
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
EP0616812B1 (fr) 1993-03-24 1999-11-03 Berlex Biosciences Combinaison d'agents anti-hormonause et molécules de liaison pour le traitement du cancer
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
WO1999014226A2 (fr) 1997-09-12 1999-03-25 Exiqon A/S Analogues d'oligonucleotides
EP1463818A2 (fr) * 2001-12-14 2004-10-06 Incyte Genomics, Inc. Transporteurs et canaux ioniques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080842A2 (fr) * 2001-04-05 2002-10-17 Estetecon Ab Medicament et procede de diagnostic d'un etat auto-immun

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 17 October 2002 (2002-10-17), SWANBECK G. ET AL.: "DNA encoding human autoimmune disease associated protein PAT1", XP002975783, Database accession no. ABX56570 *
DATABASE GENBANK [online] 2 July 2002 (2002-07-02), HEWETT D.R. ET AL.: "Identification of a novel solute carrier (SLC12A8) within an area associated with psoriasis", XP002975782, Database accession no. AF390442 *
See also references of EP1608967A4 *

Also Published As

Publication number Publication date
AU2003237792A8 (en) 2004-11-23
CA2519241A1 (fr) 2004-11-11
EP1608967A2 (fr) 2005-12-28
JP2007521791A (ja) 2007-08-09
AU2003237792A1 (en) 2004-11-23
EP1608967A4 (fr) 2006-08-09
WO2004096124A2 (fr) 2004-11-11

Similar Documents

Publication Publication Date Title
WO2003088808A3 (fr) Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
WO2006029183A3 (fr) Compositions et procedes pour le diagnostic et le traitement d'une tumeur
WO2003024392A3 (fr) Compositions et procedes pour le diagnostic et le traitement des tumeurs
WO2003000113A3 (fr) Compositions et procedes destines au diagnostic et au traitement de tumeurs
WO2007001851A3 (fr) Préparations et méthodes pour le diagnostic et le traitement d'une tumeur
WO2002016429A3 (fr) Compositions et procedes de diagnostic et traitement de tumeurs
WO2004112829A3 (fr) Compositions et procedes pour le diagnostic et le traitement de tumeurs d'origine gliale
WO2006110760A3 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
MXPA05005107A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
EP2067472A8 (fr) Compositions et procédés pour le traitement et le diagnostic d'une tumeur
WO2004030615A8 (fr) Compositions et procedes de diagnostic et de traitement de tumeur
WO2004016225A8 (fr) Compositions et methodes de diagnostic et de traitement des tumeurs
EP1571968A3 (fr) Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
WO2005049075A3 (fr) Compositions et methodes de traitement d'une tumeur d'origine hematopoietique
WO2004060270A8 (fr) Compositions et methodes pour diagnostiquer et traiter des tumeurs
WO2002016581A3 (fr) Compositions et methodes pour le diagnostic et le traitement de tumeurs
AU2003290605A1 (en) Compositions and methods for the diagnosis and treatment of sepsis
WO2004024063A3 (fr) Compositions et procede de diagnostic et de traitement des tumeurs
WO2005063299A3 (fr) Compositions et methodes pour traitement des tumeurs d'origine hematopoietique
WO2004096124A3 (fr) Compositions et procedes pour le diagnostic et le traitement de tumeurs
WO2002016602A3 (fr) Compositions et procedes conçus pour le diagnostic et le traitement de tumeur
WO2005003154A8 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
WO2006014335A3 (fr) Compositions et procedes pour le traitement de lymphome non hodgkinien
MXPA05008293A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
WO2006081272A3 (fr) Compositions et methodes de diagnostic et de traitement d'une tumeur

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2519241

Country of ref document: CA

Ref document number: 2003736450

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004571401

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003736450

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载